{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:03:08Z","timestamp":1790337788271,"version":"4.1.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors provide durable benefit in mismatch repair-deficient colorectal cancer, but most microsatellite-stable tumors remain resistant, particularly in the presence of liver metastases. Immune resistance in colorectal cancer liver metastasis reflects both baseline MSS-CRC mechanisms, including low neoantigenicity, limited T-cell priming and tumor-intrinsic immune exclusion, and liver-specific or liver-amplified mechanisms, including tolerogenic antigen presentation by hepatic resident cells, macrophage-mediated loss of tumor-reactive T cells, and hepatic stromal, vascular and metabolic remodeling. Across early-phase and retrospective studies, responses to checkpoint-based combinations have been observed more often in patients without active liver metastases, but these exploratory subgroup findings do not yet establish independent predictive value or clinical causality. Antiangiogenic agents, multikinase inhibitors, myeloid- and stromal-targeted therapies, innate immune activation, and liver-directed interventions may partially overcome these barriers, but single-pathway strategies have shown limited efficacy. This Mini Review summarizes the mechanisms and clinical evidence of liver-mediated immune resistance and proposes organ-informed, mechanism-matched therapeutic strategies for colorectal cancer liver metastasis.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1978050","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:33:18Z","timestamp":1790335998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multipathway pharmacological interventions targeting liver-derived immune resistance in colorectal cancer liver metastasis"],"prefix":"10.3389","volume":"17","author":[{"given":"Miaomiao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pediatric Intensive Care Medicine, Hainan Women and Children\u2019s Medical Center, Hainan Medical University School of Pediatrics","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanqing","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care Medicine, Hainan Women and Children\u2019s Medical Center, Hainan Medical University School of Pediatrics","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care Medicine, Hainan Women and Children\u2019s Medical Center, Hainan Medical University School of Pediatrics","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care Medicine, Hainan Women and Children\u2019s Medical Center, Hainan Medical University School of Pediatrics","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.06.006","article-title":"Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"41","author":"Adam","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.01.004","article-title":"Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure","volume":"163","author":"Creasy","year":"2018","journal-title":"Surgery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02392-x","article-title":"Advancing translational research for colorectal immuno-oncology","volume":"129","author":"Thomas","year":"2023","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer: A secondary analysis of a randomized clinical trial","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1646719","article-title":"Natural killer cells in skin: a unique opportunity to better characterize the many facets of an overlooked secondary lymphoid organ","volume":"16","author":"Johnson","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132629","article-title":"The liver as a lymphoid organ","volume":"27","author":"Crispe","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1894189","article-title":"Dendritic cells in cancer immunotherapy: functional barriers, reprogramming strategies and translational challenges","volume":"17","author":"Xiao","year":"2026","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1563184","article-title":"Exploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis","volume":"13","author":"Liu","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.Ccr-21-1193","article-title":"The liver-immunity nexus and cancer immunotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194906","article-title":"Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4285\/ctr.24.0059","article-title":"Advancing immunosuppression in liver transplantation: the role of regulatory T cells in immune modulation and graft tolerance","volume":"38","author":"Han","year":"2024","journal-title":"Clin Transplant Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/82161","article-title":"Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance","volume":"6","author":"Limmer","year":"2000","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102418","article-title":"Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives","volume":"13","author":"Zeng","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105323118","article-title":"Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy","volume":"118","author":"Ho","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-21-0316","article-title":"Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2022.02.013","article-title":"Immune phenotypic linkage between colorectal cancer and liver metastasis","volume":"40","author":"Liu","year":"2022","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s41467-025-56714-z","article-title":"WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis","volume":"16","author":"Jiang","year":"2025","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-022-00922-2","article-title":"Colorectal liver metastasis: molecular mechanism and interventional therapy","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7150\/thno.72853","article-title":"The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases","volume":"12","author":"Giguelay","year":"2022","journal-title":"Theranostics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf5464","article-title":"Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","article-title":"CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis","volume":"42","author":"Zhang","year":"2024","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1599181","article-title":"Unlocking new horizons in oncology: ivonescimab\u2019s dual-target approach to anti-VEGF\/PD-1(L1) therapy","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100383","article-title":"Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis","volume":"2","author":"Wang","year":"2021","journal-title":"Cell Rep Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: A phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: A randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clcc.2026.01.003","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated advanced colorectal cancer: results from the phase II LEAP-005 study","volume":"25","author":"Victoria Ruiz","year":"2026","journal-title":"Clin Colorectal Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","article-title":"Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases","volume":"181","author":"Guo","year":"2023","journal-title":"Eur J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.917353","article-title":"Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy: A real-world study","volume":"12","author":"Nie","year":"2022","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1470729","article-title":"Recruitment of CCR2(+) tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer","volume":"7","author":"Grossman","year":"2018","journal-title":"Oncoimmunology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-025-67579-7","article-title":"Agonist signaling drives neutrophil subpopulations to promote\/inhibit colorectal cancer liver metastasis","volume":"17","author":"Xu","year":"2025","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218657","article-title":"Multi-omic profiling identifies TREM2(+) lipid-laden macrophages as inflammatory drivers and therapeutic targets of colorectal cancer liver metastasis","volume":"656","author":"Wang","year":"2026","journal-title":"Cancer Lett"},{"key":"B55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41420-023-01472-4","article-title":"SIRP\u03b1 blockade improves the antitumor immunity of radiotherapy in colorectal cancer","volume":"9","author":"Ji","year":"2023","journal-title":"Cell Death Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol Rev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40164-025-00636-5","article-title":"Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential","volume":"14","author":"Tong","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02526","article-title":"A non-interventional clinical trial assessing immune responses after radiofrequency ablation of liver metastases from colorectal cancer","volume":"10","author":"L\u00f6ffler","year":"2019","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181a38ef5","article-title":"Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon","volume":"249","author":"Nijkamp","year":"2009","journal-title":"Ann Surg"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105508","article-title":"Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)","volume":"10","author":"Seligmann","year":"2025","journal-title":"ESMO Open"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B64","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1634\/theoncologist.2019-0924","article-title":"A pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.1694","article-title":"Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review","volume":"154","author":"Datta","year":"2019","journal-title":"JAMA Surg"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-11-0268","article-title":"Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy","volume":"71","author":"Halama","year":"2011","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003620","article-title":"Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study","volume":"18","author":"Tie","year":"2021","journal-title":"PLoS Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3836","article-title":"In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis","volume":"35","author":"Roper","year":"2017","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1978050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:33:19Z","timestamp":1790335999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1978050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1978050"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1978050","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1978050"}}